These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6341485)

  • 1. Assessment of the virulence factors of group B streptococci: correlation with sialic acid content.
    Shigeoka AO; Rote NS; Santos JI; Hill HR
    J Infect Dis; 1983 May; 147(5):857-63. PubMed ID: 6341485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sialic-acid-specific lectin from Cepaea hortensis that promotes phagocytosis of a group-B, type-Ia, streptococcal strain.
    Holm SE; Bergholm AM; Wagner B; Wagner M
    J Med Microbiol; 1985 Jun; 19(3):317-23. PubMed ID: 3892008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid content and surface hydrophobicity of group B streptococci.
    Teixeira LA; Figueiredo AM; Ferreira BT; Alves VM; Nagao PE; Alviano CS; Angluster J; Silva-Filho FC; Benchetrit LC
    Epidemiol Infect; 1993 Feb; 110(1):87-94. PubMed ID: 8432327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sialic contents on the chemiluminescent response of human leucocytes to group B streptococci.
    De Paoli P; Mucignat C; Orefici G; Santini G
    Microbiologica; 1985 Oct; 8(4):379-86. PubMed ID: 3906368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in the opsonic requirements of group B streptococcus type III.
    Hastings MJ; Easmon CS
    Br J Exp Pathol; 1981 Oct; 62(5):519-25. PubMed ID: 7028075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A search for new group-B streptococcal serotypes.
    Motlová J; Wagner M; Jelínková J
    J Med Microbiol; 1986 Sep; 22(2):101-5. PubMed ID: 3528496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth of group B streptococci in human serum leads to increased cell surface sialic acid and decreased activation of the alternative complement pathway.
    Platt MW; Correa N; Mold C
    Can J Microbiol; 1994 Feb; 40(2):99-105. PubMed ID: 8019940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci.
    Teti G; Calapai M; Calogero G; Tomasello F; Mancuso G; Galli A; Riggio G
    Hybridoma; 1992 Feb; 11(1):13-22. PubMed ID: 1371105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial genetics and human immunity to group B streptococci.
    Adderson EE; Takahashi S; Bohnsack JF
    Mol Genet Metab; 2000; 71(1-2):451-4. PubMed ID: 11001839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic variability of X-protein expression by mastitis-causing Streptococcus agalactiae of serotype NT/X and opsonic activities of specific antibodies.
    Rainard P; Sarradin P; Poutrel B
    Microb Pathog; 1994 May; 16(5):359-72. PubMed ID: 7815919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease production by clinical isolates of type III group B streptococci.
    Straus DC; Mattingly SJ; Milligan TW; Doran TI; Nealon TJ
    J Clin Microbiol; 1980 Sep; 12(3):421-3. PubMed ID: 7012176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-electronmicroscopic demonstration of capsules on group-B streptococci of new serotypes and type candidates.
    Rýc M; Jelínková J; Motlová J; Wagner M
    J Med Microbiol; 1988 Feb; 25(2):147-9. PubMed ID: 3276898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of type III group B streptococcal mutants defective in biosynthesis of the type-specific antigen.
    Yeung MK; Mattingly SJ
    Infect Immun; 1983 Oct; 42(1):141-51. PubMed ID: 6352490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci.
    Marques MB; Kasper DL; Pangburn MK; Wessels MR
    Infect Immun; 1992 Oct; 60(10):3986-93. PubMed ID: 1398910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model.
    Durham DL; Mattingly SJ; Doran TI; Milligan TW; Straus DC
    Infect Immun; 1981 Nov; 34(2):448-54. PubMed ID: 7030959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group B streptococci: extracellular neuraminidase production and virulence in mouse.
    Orefici G; De Stasio A; Guarino M; Martini A; Orsi N
    Microbiologica; 1984 Jan; 7(1):75-8. PubMed ID: 6374384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanisms in neonatal GBS infection.
    Ayoub EM; Swingle H
    Antibiot Chemother (1971); 1985; 35():128-41. PubMed ID: 3901890
    [No Abstract]   [Full Text] [Related]  

  • 19. Strain specificity of opsonins for group B streptococci types II and III.
    Shigeoka AO; Hall RT; Hill HR
    Infect Immun; 1979 Feb; 23(2):438-45. PubMed ID: 370017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence of strains of new types and type candidates of group B streptococci (Streptococcus agalactiae). Comparative evaluation using mice and a chicken embryo model.
    Wagner M; Kaatz M
    Adv Exp Med Biol; 1997; 418():819-21. PubMed ID: 9331778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.